
-
Dynavax Technologies NASDAQ:DVAX Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Location: 2100 Powell Street, Suite 900, California, 94608, US | Website: www.dynavax.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.11B
Cash
713.8M
Avg Qtr Burn
N/A
Short % of Float
19.10%
Insider Ownership
0.48%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MVC-COV1901 Details COVID-19 Vaccine | Approved Update | |
COVID-19 S-Trimer (with Clover Biopharmaceuticals) Details Infectious disease, COVID-19 | Approved Quarterly sales | |
CpG 1018 Details COVID-19 | Approved Quarterly sales | |
Heplisav-B Details Infectious disease, Hepatitis B vaccine, Hepatitis B | Approved Quarterly sales | |
Heplisav-B Details Infectious disease, Hepatitis B vaccine, Hepatitis B | BLA Resubmission | |
Phase 2 Initiation | ||
Z-1018 (adjuvanted w/ CpG 1018) Details Shingles, Infectious disease, Viral infection | Phase 1/2 Data readout | |
VLA2001 Details Infectious disease, COVID-19 | Failed Discontinued | |
Tdap-1018 (adjuvanted w/ CpG 1018) Details Infectious disease, Tetanus, diphtheria, and pertussis | Failed Discontinued |